Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy

This publication has 29 references indexed in Scilit:

• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
  New England Journal of Medicine, 2003
• Challenges in the endocrine management of breast cancer
  The Breast, 2003
• The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months
  Breast Cancer Research and Treatment, 2003
• Chemotherapy-Induced Amenorrhea and Fertility in Women Undergoing Adjuvant Treatment for Breast Cancer
  Cancer Control, 2002
• The role of bisphosphonates in breast cancer: Development of bisphosphonates
  Breast Cancer Research, 2001
• Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
  Cancer, 2000
• Skeletal complications of malignancy
  Cancer, 1997
• Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
  Journal of Bone and Mineral Research, 1994
• MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER
  The Lancet, 1986